|
|
|
|
LEADER |
00000cam a2200000 a 4500 |
001 |
SCIDIR_ocn956520504 |
003 |
OCoLC |
005 |
20231120112127.0 |
006 |
m o d |
007 |
cr |n||||||||| |
008 |
160812s2016 enk ob 001 0 eng d |
040 |
|
|
|a IDEBK
|b eng
|e pn
|c IDEBK
|d N$T
|d EBLCP
|d OPELS
|d OCLCF
|d N$T
|d OCLCQ
|d QCL
|d OCLCQ
|d U3W
|d D6H
|d YDX
|d OCLCO
|d MERER
|d OCLCQ
|d OCLCO
|d WYU
|d OCLCO
|d OCLCQ
|d OCLCA
|d OCLCQ
|d S2H
|d OCLCO
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 961930699
|a 993591641
|a 1006322204
|a 1066430837
|a 1086096859
|
020 |
|
|
|a 0128033134
|q (electronic bk.)
|
020 |
|
|
|a 9780128033135
|q (electronic bk.)
|
020 |
|
|
|z 9780128033128
|
020 |
|
|
|z 0128033126
|
035 |
|
|
|a (OCoLC)956520504
|z (OCoLC)961930699
|z (OCoLC)993591641
|z (OCoLC)1006322204
|z (OCoLC)1066430837
|z (OCoLC)1086096859
|
050 |
|
4 |
|a RC667
|
060 |
|
4 |
|a 2016 J-254
|
060 |
|
4 |
|a WG 120
|
072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
082 |
0 |
4 |
|a 616.1
|2 23
|
245 |
0 |
0 |
|a Cardiovascular diseases :
|b genetic susceptibility, environmental factors and their interaction /
|c edited by Nikolaos Papageorgiou.
|
260 |
|
|
|a London, United Kingdom :
|b Academic Press,
|c 2016.
|
300 |
|
|
|a 1 online resource (254)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a Front Cover; Cardiovascular Diseases; Cardiovascular Diseases: Genetic Susceptibility, Environmental Factors and their Interaction; Copyright; Dedication; Contents; List of Contributors; Acknowledgments; 1 -- Summary ; 2 -- Atherosclerosis and Coronary Artery Disease: From Basics to Genetics ; INTRODUCTION; NORMAL ARTERY STRUCTURES; PATHOGENESIS OF ATHEROSCLEROSIS; INITIATION OF ATHEROMA; The Role of Endothelium; The Role of LDL Particles; The Role of Inflammation; Monocyte-Derived Macrophages; LDL and Inflammation; Atheroprotective Mechanisms and Inflammation; Retention of Macrophages.
|
505 |
8 |
|
|a T LymphocytesTHE FORMATION OF ATHEROSCLEROTIC PLAQUE; Apoptosis and Efferocytosis of Macrophages; The Role of Vascular Smooth Muscle Cells; Neovascularization; CLINICAL IMPLICATIONS OF ATHEROSCLEROSIS; GENETICS OF CORONARY ARTERY DISEASE; ABO Blood Groups; Lipid-Associated Genes; Other Atherosclerosis-Related Genes; The Role of microRNAs; ATHEROSCLEROSIS: THERAPEUTIC OPTIONS; REFERENCES; 3 -- The Role of Genetics in Acute Coronary Syndrome ; INTRODUCTION; CLOPIDOGREL; Metabolism and Pharmacokinetics; Absorption and Role of P-glycoprotein; Hepatic Carboxylation and Oxidation.
|
505 |
8 |
|
|a Effect of Genotypic PolymorphismsABCB1; CYP2C19; Nomenclature; CYP2C19*2 and Other Loss-of-Function Alleles; Pharmacokinetics/Pharmacodynamics; Clinical Trials and Meta-analyses; CYP2C19*17 Gain of Function Allele; Incidence of CYP2C19 Alleles in Specific Ethnic Groups; CYP3A4; CYP1A2; Paraoxonase 1; CYP4F2; Platelet Surface Receptors; P2Y12 Receptor; Platelet Endothelial Aggregation Receptor-1; Protease Activated Receptors; Nongenetic Factors; Clopidogrel and Proton Pump Inhibitors; PRASUGREL; Metabolism; Pharmacokinetics, Pharmacodynamics, and Clinical Trials; TICAGRELOR; Metabolism.
|
505 |
8 |
|
|a Pharmacokinetics, Pharmacodynamics, and Clinical TrialsCompliance; Drug-Drug Interactions; GENOTYPING ASSAYS; COST-EFFECTIVENESS OF GENOTYPING; GENETIC POLYMORPHISMS RELATED TO ASPIRIN; FUTURE DIRECTIONS; Cilostazol and Role of Genetics; Statins and the Role of Genetics; SUMMARY: ROLE OF GENOTYPING IN ACUTE CORONARY SYNDROME; REFERENCES; 4 -- Global Epidemiology and Incidence of Cardiovascular Disease ; INTRODUCTION; GLOBAL BURDEN OF DISEASE: REPORTING METRICS; MEASURING THE GLOBAL BURDEN OF CARDIOVASCULAR DISEASE; Limitations of the Quality and Completeness of Data.
|
505 |
8 |
|
|a CHANGES IN TOTAL DISEASE BURDEN VERSUS CVDGLOBAL CARDIOVASCULAR MORTALITY; Global CVD Mortality Rates by WHO Region; Global CVD Mortality Rates by WHO/World Bank Region; Age and Gender Global CVD Mortality Rates; GLOBAL CARDIOVASCULAR DALY; Global CVD Lost DALYs Within WHO Regions; Global CVD Lost DALYs by WHO/World Bank Region; Age and Gender Global CVD Loss of DALYs; RISK FACTORS FOR CVD GLOBALLY; Hypertension; Diabetes Mellitus; Tobacco; Dyslipidemia; Physical Activity; Alcohol Consumption; EPIDEMIOLOGICAL TRANSITION; AGING POPULATION; ETHNICITY; European; Chinese; South Asian; Hispanic.
|
504 |
|
|
|a Includes bibliographical references and index.
|
650 |
|
0 |
|a Cardiovascular system
|x Diseases.
|
650 |
|
0 |
|a Cardiovascular system
|x Diseases
|x Genetic aspects.
|
650 |
1 |
2 |
|a Cardiovascular Diseases
|x genetics
|0 (DNLM)D002318Q000235
|
650 |
1 |
2 |
|a Cardiovascular Diseases
|x etiology
|0 (DNLM)D002318Q000209
|
650 |
|
2 |
|a Cardiovascular Diseases
|0 (DNLM)D002318
|
650 |
2 |
2 |
|a Genetic Predisposition to Disease
|0 (DNLM)D020022
|
650 |
2 |
2 |
|a Environment
|0 (DNLM)D004777
|
650 |
|
6 |
|a Appareil cardiovasculaire
|x Maladies.
|0 (CaQQLa)201-0057760
|
650 |
|
6 |
|a Appareil cardiovasculaire
|0 (CaQQLa)201-0057760
|x Maladies
|0 (CaQQLa)201-0057760
|x Aspect g�en�etique.
|0 (CaQQLa)201-0377534
|
650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
650 |
|
7 |
|a Cardiovascular system
|x Diseases
|2 fast
|0 (OCoLC)fst00847181
|
650 |
|
7 |
|a Cardiovascular system
|x Diseases
|x Genetic aspects
|2 fast
|0 (OCoLC)fst00847194
|
700 |
1 |
|
|a Papageorgiou, Nikolaos.
|
776 |
0 |
8 |
|i Print version:
|t Cardiovascular diseases.
|d London, United Kingdom : Academic Press, 2016
|z 9780128033128
|z 0128033126
|w (OCoLC)900032389
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128033128
|z Texto completo
|